02:53 PM EST - Cardiome Pharma Corp. : Announced the publication of results from an open label, single-centre, randomized controlled study conducted by independent researchers at the Medical University of Vienna in Vienna, Austria. It compared the time to conversion to sinus rhythm (SR) and conversion rate within 90 minutes in patients with recent-onset atrial fibrillation (AF) (<48 hrs duration) treated in the emergency department with BRINAVESS® (vernakalant IV, n=49) or ibutilide. Cardiome Pharma Corp.
shares T.COM are trading unchanged at $5.50.
